骨髄増殖性疾患治療の世界市場：洞察、競合情勢、市場予測：2032年

骨髄増殖性疾患治療の市場規模は、2025年から2032年までの予測期間中にCAGR 4.91％で成長すると予測されます。骨髄増殖性疾患（MPD）治療に対する需要は、市場の力強い成長軌道を浮き彫りにする重要な要因の集結によって、著しい急増を経験しています。その最たるものが、世界人口の高齢化、疾患に対する意識の高まり、診断能力の向上などに後押しされたMPDの有病率の増加です。これと並行して、分子診断学の急速な進歩と標的治療の開発により、これらの疾患の管理は一変し、早期発見、より正確な治療レジメン、患者の転帰の改善が可能になっています。これらの動向を総合すると、持続的な技術革新と投資にとって非常に有利な環境が形成され、MPD治療市場は2025年から2032年までの予測期間において堅調かつ持続的な成長を遂げるものと思われます。

骨髄増殖性疾患治療市場力学：

白血病財団（2025年）によると、オーストラリアでは毎年約250例の真性多血症と200例の本態性血小板血症が新たに診断されています。骨髄線維症は年間約150例で、骨髄増殖性新生物（MPN）の希少亜型は合わせて年間50例未満でした。

従って、真性多血症（PV）、本態性血小板血症（ET）、骨髄線維症（MF）を含む骨髄増殖性疾患の症例の増加は、世界の患者数を著しく拡大しています。このような疾病負担の増大により、症状の管理、QOLの向上、合併症リスクの軽減に役立つ、効果的で的を絞った長期的な治療選択肢に対する需要が高まっています。

米国では、米国国立がん研究所（National Cancer Institute）のSurveillance, Epidemiology, and End Results（SEER）プログラム（2023年）によると、MPNの新規症例は年間約2万例と診断され、約2万95,000人がMPNとともに生活していると推定されています。

同様に、米国国立衛生研究所（2023年）のデータによると、MPNは英国では10万人中約8人が罹患しています。このような症例は、過剰な血液細胞の産生を減らすために骨髄の活動を抑制することによって機能する骨髄増殖性疾患の効果的な治療に対する需要を促進しています。

さらに、骨髄増殖性疾患治療のための革新的な治療法の開発と商業化を目指した研究開発（R&D）活動への投資も活発化しています。例えば、2024年12月、Vanda Pharmaceuticals Inc.は、希少な血液悪性腫瘍である真性多血症の治療薬として開発された、選択的アンチセンス・オリゴヌクレオチド（ASO）ベースのJAK2阻害剤であるVGT-1849Aが、米国食品医薬品局（FDA）から希少疾病用医薬品に指定されたと発表しました。このような規制上のマイルストーンや製品の進歩は、骨髄増殖性疾患治療市場の成長を大きく促進すると予想されます。

これらの疾患に対する認識が高まるにつれ、診断能力や疾患モニタリングの改善とともに、より多くの患者が特定され、効果的に管理されるようになっています。こうした動向は、2025年から2032年までの予測期間において、骨髄増殖性疾患治療市場の大幅な成長を促進すると予想されます。

しかし、骨髄増殖性疾患治療薬に関連する合併症や安全性の懸念、厳しい規制当局の承認などは、骨髄増殖性疾患治療市場の成長を制限する可能性のある主要な制約事項の一部です。

骨髄増殖性疾患治療市場セグメント分析：

薬剤クラス別（阻害剤［JAK阻害剤、チロシンキナーゼ阻害剤、STAMP阻害剤、タンパク質合成阻害剤］、インターフェロン）、治療タイプ別（標的療法、免疫療法、化学療法）、適応症別（慢性骨髄性白血病（CML）、ベラ型多血症（PV）、骨髄線維症、本態性血小板血症（ET））、投与経路（経口、皮下）、流通チャネル（小売・病院薬局、オンライン薬局）、地域（北米、欧州、アジア太平洋、その他の地域）。

骨髄増殖性疾患治療市場の薬剤クラス別では、JAK阻害薬（JAKis）カテゴリーが2024年に最大の市場シェアを占めると推定されます。このカテゴリーの成長は主に、骨髄線維症（MF）や真性多血症（PV）などの疾患の有病率が上昇していることに起因しています。この成長はさらに、これらの標的薬剤の臨床効果の実証、治療用途の拡大、製品承認によって支えられています。

JAK阻害剤は、特にMF患者において、脾臓の大きさを大幅に縮小し、疲労、寝汗、骨痛などの負担の大きい体質的症状を緩和し、全体的なQOLを改善する効果が証明されています。PVでは、これらの薬剤は、ヒドロキシ尿素のような従来の治療では不十分であったり、忍容性が低かったりする場合に、ヘマトクリットコントロールを維持するのに特に有益です。

ルキソリチニブやフェドラチニブのような注目すべき治療薬は、特に標準治療に抵抗性あるいは不耐容の患者に対して大きな臨床的利益をもたらしています。これらの薬剤は、血液学的パラメーターを改善するだけでなく、生存期間を延長する可能性も示しており、骨髄増殖性新生物（MPN）の進化する管理における中心的な役割を強化しています。このカテゴリーの躍進は、主要製薬企業による継続的なイノベーションによってさらに強化されています。例えば、2023年7月、Karyopharm Therapeuticsは、原発性骨髄線維症、必須血小板血症後骨髄線維症、真性多血症後骨髄線維症を含む骨髄線維症の治療薬として開発中の新規薬剤であるセリネキソールについて、米国食品医薬品局（FDA）からファスト・トラック指定を受けました。このような規制上のマイルストーンは、これらの薬剤の治療可能性を証明するだけでなく、開発および市場開拓を加速させるものです。

JAK阻害剤の経口投与と一般的に管理しやすい安全性プロファイルは、FDAや欧州医薬品庁（EMA）などの主要機関からの承認と相まって、日常臨床での採用をさらに促進しています。さらに、本態性血小板血症（ET）や併用治療レジメンにおけるJAK阻害剤の使用に関する研究が進行中であり、MPN領域におけるJAK阻害剤の治療有用性が拡大しています。骨髄増殖性新生物に対する認識が高まり続け、より個別化された標的治療アプローチへとパラダイムシフトが進むにつれて、JAK阻害剤のような先進的治療薬に対する需要は着実に増加すると予想されます。この動向は、JAK阻害剤を将来のMPD治療の礎石と位置づけるものです。

したがって、上記の要因により、JAK阻害剤のサブカテゴリーは大きな成長を記録し、それによって2025年から2032年までの予測期間中に骨髄増殖性疾患治療市場全体の成長を牽引すると予想されます。

北米が骨髄増殖性疾患治療市場全体を支配すると予想される：

2024年には北米が骨髄増殖性疾患治療で最大のシェアを占めると予想されます。この優位性は主に、真性多血症（PV）、本態性血小板血症（ET）、骨髄線維症（MF）といった疾患の有病率の高さと、ヘルスケアプロバイダーや患者の間で疾患に対する認識が高まっていることに起因しています。加えて、主要な市場参入企業による研究開発活動や製品上市の増加も、この地域の市場地位の向上に寄与しています。

米国がん協会のデータ（2025年）によると、米国では毎年約9,560例の慢性骨髄性白血病（CML）が新たに診断されており、その内訳は男性が約5,610例、女性が約3,950例です。CMLは新たに診断された白血病症例の約15％を占め、CMLの生涯開発リスクはおよそ526分の1です。さらに、診断時の平均年齢は約64歳で、全症例のほぼ半数が65歳以上の高齢者に発症しています。CMLは主に成人が罹患し、小児ではまれと考えられています。

しかし、CMLをはじめとする骨髄増殖性新生物は慢性疾患であるため、継続的な治療とモニタリングが必要であり、その結果、標的治療薬の普及が進んでいます。これらの疾患は若年者では稀であるため、診断能力と治療プロトコルの進歩に支えられた成人・老年者医療に焦点が移っています。

さらに、これらの疾患の有病率が上昇を続ける北米では、大手製薬企業による製品上市が骨髄増殖性疾患治療市場の成長をさらに加速させています。その顕著な例が、2023年9月に米国食品医薬品局（FDA）から承認されたOjjaara（モメロチニブ）です。GSK plcによって開発されたオジャアラは、原発性骨髄線維症および二次性骨髄線維症（真性多血症後または必須血小板血症後に起因する）を含む中等度または高リスクの骨髄線維症、特に貧血を伴う成人の治療薬として承認されています。オジャアラは、1日1回経口投与のJAK1/JAK2およびアクチビンA受容体1型（ACVR1）阻害剤であり、基礎疾患と関連する貧血の両方に対処する差別化された作用機序を提供します。

このように、前述のすべての要因が相互に作用することで、2025年から2032年までの予測期間中、骨髄増殖性疾患治療市場の地域市場が活性化するとみられます。

骨髄増殖性疾患治療市場の主要参入企業

骨髄増殖性疾患治療市場で事業を展開する主要な市場参入企業には、Novartis AG、Incyte Corporation、Bristol Myers Squibb、CTI BioPharma、GSK、PharmaEssentia、Shire、Pfizer、武田薬品工業、Teva Pharmaceuticals、Merckなどが含まれます。

骨髄増殖性疾患治療市場における最近の開発活動：

• 2023年9月、GSKは米国食品医薬品局（FDA）より、貧血を伴う原発性骨髄線維症および真性多血性貧血または本態性血小板血症に起因する二次性骨髄線維症を含む、中リスクまたは高リスクの骨髄線維症の成人の治療薬としてOjjaara（モメロチニブ）が承認されたと発表しました。

骨髄増殖性疾患治療市場調査報告書の主要なポイント

• 現在の骨髄増殖性疾患治療市場規模分析（2024年）、8年間（2025年～2032年）の市場予測
• 過去3年間に起こった主な製品/技術開発、合併、買収、提携、合弁事業
• 骨髄増殖性疾患治療市場を独占する主要企業
• 骨髄増殖性疾患治療市場において競合他社が利用できる様々な機会
• 2024年に上位を占めるセグメントは何か？2032年におけるこれらのセグメントの業績
• 現在の骨髄増殖性疾患治療市場シナリオにおいて、上位の業績を上げている地域と国
• 今後、骨髄増殖性疾患治療市場成長の機会に企業が集中すべき地域や国

この骨髄増殖性疾患治療市場調査レポートから利益を得ることができる対象者

• 骨髄増殖性疾患治療製品提供者
• 研究機関およびコンサルティング会社
• 骨髄増殖性疾患治療関連団体、協会、フォーラム、その他のアライアンス
• 政府機関および企業
• 新興会社、ベンチャーキャピタル、非公開会社
• 骨髄増殖性疾患治療を扱う流通業者および貿易業者
• 骨髄増殖性疾患治療市場および骨髄増殖性疾患治療市場の最新技術開拓について詳しく知りたい各種エンドユーザー

骨髄増殖性疾患治療市場のよくある質問

1.骨髄増殖性疾患治療

• 骨髄増殖性疾患（MPD）は、より一般的には骨髄増殖性新生物（MPN）と呼ばれ、クローン性造血幹細胞障害から生じるまれな血液がんの一群です。MPNは、骨髄において赤血球、白血球、血小板を含む1種類以上の成熟した血液細胞が過剰に産生されることを特徴とします。この過剰産生は、通常、JAK2、CALR、MPLなどの細胞増殖を制御する遺伝子の変異別引き起こされ、造血細胞の異常増殖と機能につながります。

2.骨髄増殖性疾患治療市場

• 骨髄増殖性疾患治療薬市場は、2025年から2032年までの予測期間中にCAGR 4.91%で成長すると予測されています。

3.骨髄増殖性疾患治療市場の促進要因

• 骨髄増殖性疾患（MPD）治療に対する需要は、市場の力強い成長軌道を浮き彫りにする重要な要因の集結別、著しい急増を経験しています。その最たるものが、世界人口の高齢化、疾患に対する意識の高まり、診断能力の向上などに後押しされたMPDの有病率の増加です。これと並行して、分子診断学の急速な進歩と標的治療の開発により、これらの疾患の管理は一変し、早期発見、より正確な治療レジメン、患者の転帰の改善が可能になっています。これらの動向を総合すると、持続的な技術革新と投資にとって非常に有利な環境が形成され、MPD治療市場は2025年から2032年までの予測期間において堅調かつ永続的な成長を遂げるものと思われます。

4.骨髄増殖性疾患治療市場で事業を展開する主要企業は？

• 骨髄増殖性疾患治療薬市場で事業を展開している主な市場参入企業には、Novartis AG、Incyte Corporation、Bristol Myers Squibb、CTI BioPharma、GSK、PharmaEssentia、Shire、Pfizer、武田薬品工業、Teva Pharmaceuticals、Merckなどがあります。

5.骨髄増殖性疾患治療薬市場で最もシェアが高い地域

• 北米は、2025年から2032年までの予測期間中、骨髄増殖性疾患治療で最大のシェアを占めると予想されています。この優位性は主に、真性多血症（PV）、本態性血小板血症（ET）、骨髄線維症（MF）といった疾患の有病率の高さと、ヘルスケアプロバイダーや患者の間で疾患に対する認識が高まっていることに起因しています。さらに、主要な市場参入企業別研究開発活動や製品上市の増加が、同地域の市場地位の向上に貢献しています。

目次

第1章 骨髄増殖性疾患治療市場レポートのイントロダクション

第2章 骨髄増殖性疾患治療市場のエグゼクティブサマリー

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 骨髄増殖性疾患治療市場の主な要因分析

• 骨髄増殖性疾患治療市場促進要因
  • 骨髄増殖性疾患の有病率の上昇
  • 分子診断と標的治療の進歩
• 骨髄増殖性疾患治療市場抑制要因と課題
  • 骨髄増殖性疾患治療薬に伴う合併症および安全性の懸念
  • 厳格な規制承認
• 骨髄増殖性疾患治療市場の機会
  • 骨髄増殖性疾患の治療法開発のための研究開発と臨床試験の増加

第6章 骨髄増殖性疾患治療市場におけるポーターのファイブフォース分析

第7章 骨髄増殖性疾患治療市場の評価

• 薬剤クラス別
  • 阻害剤
  • インターフェロン
• 治療タイプ別
  • 標的療法
  • 免疫療法
  • 化学療法
• 適応症別
  • 慢性骨髄性白血病（CML）
  • 真性多血症（PV）
  • 骨髄線維症
  • 原発性血小板血症（ET）
• 投与経路
  • 経口
  • 皮下
• 流通チャネル別
  • 小売薬局および病院薬局
  • オンライン薬局
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 骨髄増殖性疾患治療市場の企業と製品プロファイル

• Novartis AG
• Incyte Corporation
• Bristol Myers Squibb
• CTI BioPharma
• GSK
• PharmaEssentia
• Shire
• Pfizer
• Takeda
• Teva Pharmaceuticals
• Merck

第9章 KOLの見解

第10章 プロジェクトアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Myeloproliferative Disorder Treatment Market in Global (2022-2032)
• Table 3: Myeloproliferative Disorder Treatment Market in Global by Drug Class (2022-2032)
• Table 4: Myeloproliferative Disorder Treatment Market in Global by Treatment Type (2022-2032)
• Table 5: Myeloproliferative Disorder Treatment Market in Global by Indication (2022-2032)
• Table 6: Myeloproliferative Disorder Treatment Market in Global by Route of Administration (2022-2032)
• Table 7: Myeloproliferative Disorder Treatment Market in Global by Distribution Channel (2022-2032)
• Table 8: Myeloproliferative Disorder Treatment Market in Global by Geography (2022-2032)
• Table 9: Myeloproliferative Disorder Treatment Market in North America (2022-2032)
• Table 10: Myeloproliferative Disorder Treatment Market in the United States (2022-2032)
• Table 11: Myeloproliferative Disorder Treatment Market in Canada (2022-2032)
• Table 12: Myeloproliferative Disorder Treatment Market in Mexico (2022-2032)
• Table 13: Myeloproliferative Disorder Treatment Market in Europe (2022-2032)
• Table 14: Myeloproliferative Disorder Treatment Market in France (2022-2032)
• Table 15: Myeloproliferative Disorder Treatment Market in Germany (2022-2032)
• Table 16: Myeloproliferative Disorder Treatment Market in United Kingdom (2022-2032)
• Table 17: Myeloproliferative Disorder Treatment Market in Italy (2022-2032)
• Table 18: Myeloproliferative Disorder Treatment Market in Spain (2022-2032)
• Table 19: Myeloproliferative Disorder Treatment Market in the Rest of Europe (2022-2032)
• Table 20: Myeloproliferative Disorder Treatment Market in Asia-Pacific (2022-2032)
• Table 21: Myeloproliferative Disorder Treatment Market in China (2022-2032)
• Table 22: Myeloproliferative Disorder Treatment Market in Japan (2022-2032)
• Table 23: Myeloproliferative Disorder Treatment Market in India (2022-2032)
• Table 24: Myeloproliferative Disorder Treatment Market in Australia (2022-2032)
• Table 25: Myeloproliferative Disorder Treatment Market in South Korea (2022-2032)
• Table 26: Myeloproliferative Disorder Treatment Market in Rest of Asia-Pacific (2022-2032)
• Table 27: Myeloproliferative Disorder Treatment Market in the Rest of the World (2022-2032)
• Table 28: Myeloproliferative Disorder Treatment Market in the Middle East (2022-2032)
• Table 29: Myeloproliferative Disorder Treatment Market in Africa (2022-2032)
• Table 30: Myeloproliferative Disorder Treatment Market in South America (2022-2032)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Myeloproliferative Disorder Treatment Market in Global (2022-2032)
• Figure 3: Myeloproliferative Disorder Treatment Market in Global by Drug Class (2022-2032)
• Figure 4: Myeloproliferative Disorder Treatment Market in Global by Treatment Type (2022-2032)
• Figure 5: Myeloproliferative Disorder Treatment Market in Global by Indication (2022-2032)
• Figure 6: Myeloproliferative Disorder Treatment Market in Global by Route of Administration (2022-2032)
• Figure 7: Myeloproliferative Disorder Treatment Market in Global by Distribution Channel (2022-2032)
• Figure 8: Myeloproliferative Disorder Treatment Market in Global by Geography (2022-2032)
• Figure 9: Myeloproliferative Disorder Treatment Market in North America (2022-2032)
• Figure 10: Myeloproliferative Disorder Treatment Market in the United States (2022-2032)
• Figure 11: Myeloproliferative Disorder Treatment Market in Canada (2022-2032)
• Figure 12: Myeloproliferative Disorder Treatment Market in Mexico (2022-2032)
• Figure 13: Myeloproliferative Disorder Treatment Market in Europe (2022-2032)
• Figure 14: Myeloproliferative Disorder Treatment Market in France (2022-2032)
• Figure 15: Myeloproliferative Disorder Treatment Market in Germany (2022-2032)
• Figure 16: Myeloproliferative Disorder Treatment Market in United Kingdom (2022-2032)
• Figure 17: Myeloproliferative Disorder Treatment Market in Italy (2022-2032)
• Figure 18: Myeloproliferative Disorder Treatment Market in Spain (2022-2032)
• Figure 19: Myeloproliferative Disorder Treatment Market in the Rest of Europe (2022-2032)
• Figure 20: Myeloproliferative Disorder Treatment Market in Asia-Pacific (2022-2032)
• Figure 21: Myeloproliferative Disorder Treatment Market in China (2022-2032)
• Figure 22: Myeloproliferative Disorder Treatment Market in Japan (2022-2032)
• Figure 23: Myeloproliferative Disorder Treatment Market in India (2022-2032)
• Figure 24: Myeloproliferative Disorder Treatment Market in Australia (2022-2032)
• Figure 25: Myeloproliferative Disorder Treatment Market in South Korea (2022-2032)
• Figure 26: Myeloproliferative Disorder Treatment Market in Rest of Asia-Pacific (2022-2032)
• Figure 27: Myeloproliferative Disorder Treatment Market in the Rest of the World (2022-2032)
• Figure 28: Myeloproliferative Disorder Treatment Market in the Middle East (2022-2032)
• Figure 29: Myeloproliferative Disorder Treatment Market in Africa (2022-2032)
• Figure 30: Myeloproliferative Disorder Treatment Market in South America (2022-2032)
• Figure 31: Market Drivers
• Figure 32: Market Barriers
• Figure 33: Marker Opportunities
• Figure 34: PORTER'S Five Force Analysis

Myeloproliferative Disorder Treatment Market by Drug Class (Inhibitors [JAK Inhibitors, Tyrosine Kinase Inhibitors, STAMP Inhibitor, and Protein Synthesis Inhibitor], and Interferons), Treatment Type (Targeted Therapy, Immunotherapy, and Chemotherapy), Indication (Chronic Myeloid Leukemia (CML), Polycythemia Vera (PV), Myelofibrosis, and Essential Thrombocythemia (ET)), Route of Administration (Oral and Subcutaneous), Distribution Channel (Retail & Hospital Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising prevalence of myeloproliferative disorders and advancements in molecular diagnostics and targeted therapies.

The myeloproliferative disorder treatment market is estimated to grow at a CAGR of 4.91% during the forecast period from 2025 to 2032. The demand for myeloproliferative disorder (MPD) treatment is experiencing a significant surge, driven by a convergence of critical factors that highlight the market's strong growth trajectory. Foremost among these is the increasing prevalence of MPDs, fueled by an aging global population, heightened disease awareness, and improved diagnostic capabilities. Parallel to this, rapid advancements in molecular diagnostics and the development of targeted therapies have revolutionized the management of these disorders enabling earlier detection, more precise treatment regimens, and improved patient outcomes. Collectively, these trends are cultivating a highly favorable landscape for sustained innovation and investment, positioning the MPD treatment market for robust and enduring growth over the forecast period from 2025 to 2032.

Myeloproliferative Disorder Treatment Market Dynamics:

According to the Leukaemia Foundation (2025), in Australia, approximately 250 new cases of polycythemia vera and 200 cases of essential thrombocythemia were diagnosed each year. Myelofibrosis accounted for around 150 annual diagnoses, while rarer subtypes of myeloproliferative neoplasms (MPNs) collectively affected fewer than 50 individuals per year.

Therefore, the rising cases of myeloproliferative disorders including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) are significantly expanding the global patient population. This growing disease burden is driving an increased demand for effective, targeted, and long-term treatment options that can help manage symptoms, enhance quality of life, and reduce the risk of complications.

In the United States, the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (2023), estimated that nearly 20,000 new cases of MPNs were diagnosed annually, with approximately 295,000 people living with that condition.

Similarly, data from the National Institutes of Health (2023) indicated that MPNs affect approximately 8 out of every 100,000 individuals in the UK. Such cases are driving the demand for effective treatments for myeloproliferative disorders that work by suppressing bone marrow activity to reduce the production of excess blood cells.

Moreover, leading players in the market are increasingly investing in research and development (R&D) activities aimed at developing and commercializing innovative therapies for the treatment of myeloproliferative disorders. For example, in December 2024, Vanda Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation to VGT-1849A, an investigational, selective antisense oligonucleotide (ASO)-based JAK2 inhibitor developed for the treatment of polycythemia vera (PV), a rare hematologic malignancy. Such regulatory milestones and product advancements are anticipated to significantly drive the growth of the myeloproliferative disorder treatment market.

As awareness of these conditions grows, along with improvements in diagnostic capabilities and disease monitoring, more patients are being identified and managed effectively. These trends are expected to drive substantial growth in the myeloproliferative disorder treatment market over the forecast period from 2025 to 2032.

However, the complications & safety concerns associated with myeloproliferative disorder drugs and stringent regulatory approvals, among others are some of the key constraints that may limit the growth of the myeloproliferative disorder treatment market.

Myeloproliferative Disorder Treatment Market Segment Analysis:

Myeloproliferative Disorder Treatment Market by Drug Class (Inhibitors [JAK Inhibitors, Tyrosine Kinase Inhibitors, STAMP Inhibitor, and Protein Synthesis Inhibitor], and Interferons), Treatment Type (Targeted Therapy, Immunotherapy, and Chemotherapy), Indication (Chronic Myeloid Leukemia (CML), Polycythemia Vera (PV), Myelofibrosis, and Essential Thrombocythemia (ET)), Route of Administration (Oral and Subcutaneous), Distribution Channel (Retail & Hospital Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the drug class segment of the myeloproliferative disorder treatment market, the JAK inhibitors (JAKis) category category is estimated to account for the largest market share in 2024. The growth of the category is mainly attributed to the rising prevalence of conditions such as myelofibrosis (MF) and polycythemia vera (PV). This growth is further supported by the demonstrated clinical efficacy, expanding therapeutic applications, and product approvals of these targeted drugs.

JAK inhibitors have proven effective in significantly reducing spleen size, relieving burdensome constitutional symptoms such as fatigue, night sweats, and bone pain, and improving overall quality of life, particularly in patients with MF. In PV, these agents are especially beneficial in maintaining hematocrit control in cases where conventional treatments, such as hydroxyurea, are either insufficient or poorly tolerated.

Notable therapies like Ruxolitinib and Fedratinib have delivered substantial clinical benefits, particularly for patients who are resistant to or intolerant of standard treatments. These drugs not only improve hematologic parameters but also demonstrate the potential to extend survival, reinforcing their central role in the evolving management of myeloproliferative neoplasms (MPNs). The surge in this category is further strengthened by continued innovation from leading pharmaceutical companies. For example, in July 2023, Karyopharm Therapeutics received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for Selinexor, a novel agent being developed for the treatment of myelofibrosis, including primary MF, post-essential thrombocythemia MF, and post-polycythemia vera MF. Such regulatory milestones not only validate the therapeutic potential of these drugs but also help accelerate their development and market availability.

The oral administration and generally manageable safety profile of JAK inhibitors, coupled with regulatory approvals from key agencies such as the FDA and European Medicines Agency (EMA), have further facilitated their adoption in routine clinical practice. Additionally, ongoing research into the use of JAK inhibitors in essential thrombocythemia (ET) and combination treatment regimens is broadening their therapeutic utility across the MPN spectrum. As awareness of myeloproliferative neoplasms continues to rise and the paradigm shifts toward more personalized, targeted treatment approaches, demand for advanced therapies like JAK inhibitors is expected to increase steadily. This trend positions JAK inhibitors as a cornerstone in the future landscape of MPD treatment.

Thus, due to the above-mentioned factors, the JAK inhibitors sub-category is expected to register significant growth, thereby driving the growth of the overall myeloproliferative disorder treatment market during the forecast period from 2025 to 2032.

North America is expected to dominate the overall myeloproliferative disorder treatment market:

North America is expected to hold the largest share of myeloproliferative disorder treatment in 2024. This dominance is primarily attributed to the high prevalence of conditions such as polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), coupled with greater disease awareness among healthcare providers and patients. Additionally, increasing R&D activities and product launches by key market players further contribute to the region's strong market position.

According to data from the American Cancer Society (2025), in the United States, approximately 9,560 new cases of chronic myeloid leukemia (CML) are diagnosed each year, with around 5,610 cases in men and 3,950 in women. CML accounted for about 15% of all newly diagnosed leukemia cases, and the lifetime risk of developing CML is roughly 1 in 526. Additionally, the average age at diagnosis is approximately 64 years, with nearly half of all cases occurring in individuals aged 65 and older. CML predominantly affects adults and is considered rare in children.

However, the chronic nature of CML and other myeloproliferative neoplasms requires ongoing treatment and monitoring, thereby increasing the uptake of targeted therapies. The rarity of these disorders in younger individuals shifts the focus to adult and geriatric care, which is supported by advancements in diagnostic capabilities and treatment protocols.

Moreover, product launches by major pharmaceutical players are further accelerating the growth of the myeloproliferative disorder treatment market in North America, where the prevalence of these conditions continues to rise. A notable example is the approval of Ojjaara (momelotinib) by the U.S. Food and Drug Administration (FDA) in September 2023. Developed by GSK plc, Ojjaara is approved for the treatment of adults with intermediate- or high-risk myelofibrosis, including primary myelofibrosis and secondary myelofibrosis (resulting from post-polycythemia vera or post-essential thrombocythemia), particularly in patients with anemia. Ojjaara is a once-daily oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor, offering a differentiated mechanism of action that addresses both the underlying disease and associated anemia.

Thus, the interplay of all the aforementioned factors is likely to fuel the regional market for the myeloproliferative disorder treatment market during the forecast period from 2025 to 2032.

Myeloproliferative Disorder Treatment Market Key Players:

Some of the key market players operating in the myeloproliferative disorder treatment market include Novartis AG, Incyte Corporation, Bristol Myers Squibb, CTI BioPharma, GSK, PharmaEssentia, Shire, Pfizer, Takeda, Teva Pharmaceuticals, Merck, and others.

Recent Developmental Activities in the Myeloproliferative Disorder Treatment Market:

• In September 2023, GSK announced that the U.S. Food and Drug Administration (FDA) approved Ojjaara (momelotinib) for the treatment of adults with intermediate or high-risk myelofibrosis, including both primary myelofibrosis and secondary forms arising from polycythaemia vera or essential thrombocythaemia, who also have anaemia.

Key takeaways from the myeloproliferative disorder treatment market report study

• Market size analysis for current myeloproliferative disorder treatment market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the myeloproliferative disorder treatment market.
• Various opportunities available for the other competitors in the myeloproliferative disorder treatment market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current myeloproliferative disorder treatment market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for myeloproliferative disorder treatment market growth in the coming future?

Target audience who can benefit from this myeloproliferative disorder treatment market report study

• Myeloproliferative disorder treatment product providers
• Research organizations and consulting companies
• Myeloproliferative disorder treatment-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in myeloproliferative disorder treatment
• Various end-users who want to know more about the myeloproliferative disorder treatment market and the latest technological developments in the myeloproliferative disorder treatment market

Frequently Asked Questions for the Myeloproliferative Disorder Treatment Market:

1. What is myeloproliferative disorder treatment?

• Myeloproliferative Disorders (MPDs), more commonly referred to as Myeloproliferative Neoplasms (MPNs), are a group of rare blood cancers that arise from clonal hematopoietic stem cell disorders. They are characterized by the excessive production of one or more types of mature blood cells, including red blood cells, white blood cells, or platelets in the bone marrow. This overproduction is typically driven by mutations in genes that regulate cell proliferation, such as JAK2, CALR, or MPL, leading to abnormal growth and function of blood-forming cells.

2. What is the market for myeloproliferative disorder treatment?

• The myeloproliferative disorder treatment market is estimated to grow at a CAGR of 4.91% during the forecast period from 2025 to 2032.

3. What are the drivers for the myeloproliferative disorder treatment market?

• The demand for myeloproliferative disorder (MPD) treatment is experiencing a significant surge, driven by a convergence of critical factors that highlight the market's strong growth trajectory. Foremost among these is the increasing prevalence of MPDs, fueled by an aging global population, heightened disease awareness, and improved diagnostic capabilities. Parallel to this, rapid advancements in molecular diagnostics and the development of targeted therapies have revolutionized the management of these disorders enabling earlier detection, more precise treatment regimens, and improved patient outcomes. Collectively, these trends are cultivating a highly favorable landscape for sustained innovation and investment, positioning the MPD treatment market for robust and enduring growth over the forecast period from 2025 to 2032.

4. Who are the key players operating in the myeloproliferative disorder treatment market?

• Some of the key market players operating in the myeloproliferative disorder treatment market include Novartis AG, Incyte Corporation, Bristol Myers Squibb, CTI BioPharma, GSK, PharmaEssentia, Shire, Pfizer, Takeda, Teva Pharmaceuticals, Merck, and others.

5. Which region has the highest share in the myeloproliferative disorder treatment market?

• North America is expected to hold the largest share of myeloproliferative disorder treatment during the forecast period from 2025 to 2032. This dominance is primarily attributed to the high prevalence of conditions such as polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), coupled with greater disease awareness among healthcare providers and patients. Additionally, increasing R&D activities and product launches by key market players further contribute to the region's strong market position.

Table of Contents

1. Myeloproliferative Disorder Treatment Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Myeloproliferative Disorder Treatment Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Myeloproliferative Disorder Treatment Market Key Factors Analysis

• 5.1. Myeloproliferative Disorder Treatment Market Drivers
  • 5.1.1. Rising prevalence of myeloproliferative disorders
  • 5.1.2. Advancements in molecular diagnostics and targeted therapies
• 5.2. Myeloproliferative Disorder Treatment Market Restraints and Challenges
  • 5.2.1. Complications & safety concerns associated with myeloproliferative disorder drugs
  • 5.2.2. Stringent regulatory approvals
• 5.3. Myeloproliferative Disorder Treatment Market Opportunity
  • 5.3.1. Increasing research & development and clinical trials for the development of myeloproliferative disorder therapies

6. Myeloproliferative Disorder Treatment Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Myeloproliferative Disorder Treatment Market Assessment

• 7.1. By Drug Class
  • 7.1.1. Inhibitors
    • 7.1.1.1. JAK Inhibitors
    • 7.1.1.2. Tyrosine Kinase Inhibitors
    • 7.1.1.3. STAMP Inhibitor
    • 7.1.1.4. Protein Synthesis Inhibitor
  • 7.1.2. Interferons
• 7.2. By Treatment Type
  • 7.2.1. Targeted Therapy
  • 7.2.2. Immunotherapy
  • 7.2.3. Chemotherapy
• 7.3. By Indication
  • 7.3.1. Chronic Myeloid Leukemia (CML)
  • 7.3.2. Polycythemia Vera (PV)
  • 7.3.3. Myelofibrosis
  • 7.3.4. Essential Thrombocythemia (ET)
• 7.4. By Route of Administration
  • 7.4.1. Oral
  • 7.4.2. Subcutaneous
• 7.5. By Distribution Channel
  • 7.5.1. Retail & Hospital Pharmacies
  • 7.5.2. Online Pharmacies
• 7.6. By Geography
  • 7.6.1. North America
    • 7.6.1.1. United States Myeloproliferative Disorder Treatment Market Size in USD million (2022-2032)
    • 7.6.1.2. Canada Myeloproliferative Disorder Treatment Market Size in USD million (2022-2032)
    • 7.6.1.3. Mexico Myeloproliferative Disorder Treatment Market Size in USD million (2022-2032)
  • 7.6.2. Europe
    • 7.6.2.1. France Myeloproliferative Disorder Treatment Market Size in USD million (2022-2032)
    • 7.6.2.2. Germany Myeloproliferative Disorder Treatment Market Size in USD million (2022-2032)
    • 7.6.2.3. United Kingdom Myeloproliferative Disorder Treatment Market Size in USD million (2022-2032)
    • 7.6.2.4. Italy Myeloproliferative Disorder Treatment Market Size in USD million (2022-2032)
    • 7.6.2.5. Spain Myeloproliferative Disorder Treatment Market Size in USD million (2022-2032)
    • 7.6.2.6. Rest of Europe Myeloproliferative Disorder Treatment Market Size in USD million (2022-2032)
  • 7.6.3. Asia-Pacific
    • 7.6.3.1. China Myeloproliferative Disorder Treatment Market Size in USD million (2022-2032)
    • 7.6.3.2. Japan Myeloproliferative Disorder Treatment Market Size in USD million (2022-2032)
    • 7.6.3.3. India Myeloproliferative Disorder Treatment Market Size in USD million (2022-2032)
    • 7.6.3.4. Australia Myeloproliferative Disorder Treatment Market Size in USD million (2022-2032)
    • 7.6.3.5. South Korea Myeloproliferative Disorder Treatment Market Size in USD million (2022-2032)
    • 7.6.3.6. Rest of Asia-Pacific Myeloproliferative Disorder Treatment Market Size in USD million (2022-2032)
  • 7.6.4. Rest of the World (RoW)
    • 7.6.4.1. Middle East Myeloproliferative Disorder Treatment Market Size in USD million (2022-2032)
    • 7.6.4.2. Africa Myeloproliferative Disorder Treatment Market Size in USD million (2022-2032)
    • 7.6.4.3. South America Myeloproliferative Disorder Treatment Market Size In USD Million (2022-2032)

8. Myeloproliferative Disorder Treatment Market Company and Product Profiles

• 8.1. Novartis AG
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Incyte Corporation
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Bristol Myers Squibb
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. CTI BioPharma
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. GSK
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. PharmaEssentia
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Shire
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Pfizer
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Takeda
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Teva Pharmaceuticals
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Merck
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us